Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...
Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 ...
Survey of 800+ HCPs Finds Menopause Care is the #1 Area Where Providers Expect the Greatest Improvement in the Next 5 ...
A Comprehensive Guide to the Fetal Bovine Serum MarketThe biotechnology and pharmaceutical industries are currently ...
Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumorsAuthorization follows a reliance-based ...
The Assistive Technology Market refers to the global industry focused on designing, manufacturing, and distributing devices, ...
New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various ...
A SmartSense survey of 150 U.S.-based hospital CFOs finds 94% of respondents reporting unexpected expenses related to ...
The medical landscape undergoes a rapid transformation as precision becomes the standard of care. At the heart of this ...
OverviewThe Global Medical Holographic Imaging Market is valued at USD 2.2 Billion in 2024 and is projected to reach a value ...
Rossi Brings Decades of Leadership as Convergent Advances its Alpha-based Radioantibody for Prostate Cancer to Late-Stage ...
Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatmentAP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results